Last reviewed · How we verify
FDC — Competitive Intelligence Brief
phase 3
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
FDC (FDC) — Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. FDC is a cardiovascular investigational drug developed by a Spanish research foundation, but its specific mechanism of action is not publicly disclosed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FDC TARGET | FDC | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). FDC — Competitive Intelligence Brief. https://druglandscape.com/ci/fdc. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab